To analyse data from randomised trials in which low molecular weight heparin was compared with unfractionated heparin, to estimate the treatment effect of low molecular weight heparin in the initial treatment of venous thromboembolism, with regard to recurrent venous thromboembolism, mortality and major bleeding complications. In addition, the authors wished to evaluate the effect of the varied proportion of included cancer patients on the incidence of these outcome events and on the estimated treatment effect.
Methods of synthesis
How were the studies combined? The odds ratio (OR) and 95% confidence intervals (95% CI) were calculated separately for each study and then pooled across studies to estimate a summary OR and 95% CI using the Mantel-Haenszel method. To evaluate the effect of the proportion of patients with cancer on the incidence of outcome events and on estimated treatment effect, linear regression was used.
How were differences between studies investigated? Meta-regression was used to investigate possible sources of heterogeneity.
Results of the review
Thirteen trials with a total of 4509 participants (3333 with DVT and 1176 with DVT and/or pulmonary embolism). The outcome of 3-month recurrent venous thromboembolism was evaluated in 4019 participants, the outcome of major bleeding during initial treatment was evaluated in 4506 participants, and the outcome of 3 month mortality was evaluated in 3815 participants.
Low molecular weight heparin has been extensively investigated in patients with deep vein thrombosis, but few trials have included patients with pulmonary embolism. The risk of recurrence of venous thromboembolism (odds ratio, 0.77; 95% CI, 0.56-1.04), major bleeding (odds ratio, 0.60; 95% CI, 0.38-0.95), and mortality (odds ratio, 0.72; 95% CI, 0.55-0.96) was less with low molecular weight heparins compared with unfractionated heparin. The proportion of cancer patients in these studies had a statistically significant effect on the incidence of recurrent venous thromboembolism (P = 0.03) and mortality (P = 0.002), but no influence on the estimated treatment effects of low molecular weight heparins.
Authors' conclusions
Low molecular weight heparin is effective and safe in the initial treatment of venous thromboembolism. The results of trials involving more than 400 patients justify the use of fixed-dose subcutaneous low molecular heparins in the initial treatment of venous thromboembolism. However, caution should be taken in patients with pulmonary embolism, because it is as yet not possible to arrive at a definitive conclusion with the available evidence.
CRD commentary
This was a clear and well-written review that addressed an important clinical question. The search strategy was adequate, but no systematic attempt was made to identify unpublished studies although authors were contacted for 'not yet published studies'; the possibility of publication bias cannot, therefore, be ruled out. Furthermore, the authors did not state if there were any language restrictions. The validity of the trials was not assessed but only randomised trials were included; lesser quality trials were excluded. The authors' conclusions on the effectiveness of the treatments appear to follow on from the results of the included studies. However, they make a judgement about safety of the treatment, which was not assessed in the review.
Implications of the review for practice and research
Practice: The authors state that the results of trials involving more than 400 patients justify the use of fixed-dose subcutaneous low molecular heparins in the initial treatment of venous thromboembolism. However, caution should be taken in patients with pulmonary embolism, because it is as yet not possible to arrive at a definitive conclusion with the available evidence.
Research: The authors did not state any implications for further research.
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